192

KEY REFERENCES AND WEBSITES

A full list of references for this chapter can be found at

http://thepoint.lww.com/AT11e. Below are the key references and websites for this

chapter, with the corresponding reference number in this chapter found in parentheses

after the reference.

Key References

Cardone KE et al. Medication-related problems in CKD. Adv Chronic Kidney Dis. 2010;17(5):404–412 (7)

Kalantar-Zadeh K et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic

kidney disease. Clin J Am Soc Nephrol. 2010;5(3):519–530. (133)

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice

guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–163 (1)

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice

guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone

disorder (CKD-MBD). Kidney Int Suppl. 2009;(Suppl 113):S1–S130. (92)

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice

guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274. (177)

Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO practice guideline for lipid

management in chronic kidney disease. Kidney Inter Suppl. 2013;3:259–305. (67)

Larson DS, Coyne DW. Update on intravenous iron choices. Curr Opin Nephrol Hypertens. 2014;23(2):186–191.

(106)

Key Websites

HealtyPeople2020, http://www.healthypeople.gov/.

Kidney Disease, Improving Global Outcomes: http://kdigo.org/home/.

National Kidney Disease Education Program, http://nkdep.nih.gov/.

US Renal Data System, http://www.usrds.org/.

COMPLETE REFERENCES CHAPTER 28 CHRONIC

KIDNEY DISEASE

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice

guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl (2011). 2013;3(1):1–

163.

Steinberg EP. Improving the quality of care—can we practice what we preach? N Engl J Med.

2003;348(26):2681–2683.

United States Renal Data System. USRDS 2014 Annual Data Report: Epidemiology of Kidney Disease in the

United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and

Kidney Diseases; 2014.

National Kidney Foundation. Kidney Early Evaluation Program (KEEP) 2012 summary figures. Am J Kidney Dis.

2013;61(4, Suppl 2):S33–S56.

Healthy People 2020. Chronic kidney disease. http://www.healthypeople.gov/2020/topicsobjectives/topic/chronic-kidney-disease/objectives. Accessed July 6, 2015.

Manley HJ et al. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney

Dis. 2005;46(4):669–680.

Cardone KE et al. Medication-related problems in CKD. Adv Chronic Kidney Dis. 2010;17(5):404–412.

Aspinall SL et al. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with nondialysis-dependent CKD. Am J Kidney Dis. 2012;60(3):371–379.

Pai AB et al. Health-related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: a

2-year randomized, controlled study. Hemodial Int. 2009;13(1):72–79.

Pai AB et al. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received

pharmaceutical care: a 2-year, randomized, controlled study. Pharmacotherapy. 2009;29(12):1433–1440.

Zandi-Nejad K, Brenner BM. Strategies to retard the progression of chronic kidney disease. Med Clin N Am.

2005;89(3):489–509.

Hogan SL et al. Association of cigarette smoking with albuminuria in the United States: the third National Health

and Nutrition Examination Survey. Ren Fail. 2007;29(2):133–142.

Jafar TH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and

angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244–252.

Parsa A et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med.

2013;369(23):2183–2196.

Segelmark M, Hellmark T. Autoimmune kidney diseases. Autoimmun Rev. 2010;9(5):A366–A371.

Andreev E et al. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J

Intern Med. 1999;246(3):247–252.

Appel GB et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care.

2003;26(5):1402–1407.

Boes E et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney

disease study. J Am Soc Nephrol. 2006;17(2):528–536.

Bianchi S et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of

kidney disease. Am J Kidney Dis. 2003;41(3):565–570.

Henrich WL et al. Analgesics and the kidney:summary and recommendations to the Scientific Advisory Board of

the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney

Dis. 1996;27(1):162–165.

Bennett WM et al. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations.

Am J Kidney Dis. 1996;28(1, Suppl 1):S56–S62.

Kuo HW et al. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug

Saf. 2010;19(7):745–751.

Roberts E et al. Paracetamol: not as safe as we thought? A systematic literature review of observationalstudies.

Ann Rheumat Dis. 2016;75(3):552–559.

Perneger TV et al. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal

antiinflammatory drugs. N EnglJ Med. 1994;331(25):1675–1679.

Grunfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol. 2009;5(5):270–276.

Shine B et al. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of

laboratory data. Lancet. 2015;386(9992):461–468.

Nyman HA et al. Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal

Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research

Network of the American College of Clinical Pharmacy. Pharmacotherapy. 2011;31(11):1130–1144.

Sherman DS et al. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis.

2003;41(2):269–278.

Myers GL et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory

Working Group of the National Kidney Disease Education Program. Clin Chem. 2006;52(1):5–18.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

Schwartz GJ et al. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants,

children, and adolescents. Pediatr Clin North Am. 1987;34(3):571–590.

Levey AS et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new

prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470.

Stevens LA et al. Evaluation of the modification of diet in renal disease study equation in a large diverse

population. J Am Soc Nephrol. 2007;18(10):2749–2757.

Levey AS et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.

Stevens LA et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a

pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51(3):395–406.

Poortmans JR et al. Renal protein excretion after exercise in man. Eur J Appl Physiol Occup Physiol.

1989;58(5):476–480.

Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD

patients in the United States. Am J Kidney Dis. 2003;41(2):310–318.

Keane WF, Lyle PA, Reduction of Endpoints in NwtAIIRALs. Recent advances in management of type 2

diabetes and nephropathy: lessons from the RENAAL study. Am J Kidney Dis. 2003;41(3, Suppl 1):S22–S25.

Wen CP et al. Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are

similar. Kidney Int. 2014;86(4):819–827.

Brandle E et al. Effect of chronic dietary protein intake on the renal function in healthy subjects. Eur J Clin Nutr.

1996;50(11):734–740.

Menon V et al. Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in

Renal Disease (MDRD) Study. Am J Kidney Dis. 2009;53(2):208–217.

Pedrini MT et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal

diseases: a meta-analysis. Ann Intern Med. 1996;124(7):627–632.

Klahr S et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic

renal disease. Modification of Diet in Renal Disease Study Group. N EnglJ Med. 1994;330(13):877–884.

Levey AS et al. Effects of dietary protein restriction on the progression of advanced renal disease in the

Modification of Diet in Renal Disease Study. Am J Kidney Dis. 1996;27(5):652–663.

Fouque D et al. Nutrition and chronic kidney disease. Kidney Int. 2011;80(4):348–357.

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice

guideline for the management of blood pressure in chronic kidney disease. Kindey Inter Suppl. 2012;2: 337–414.

James PA et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from

the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.

Peterson JC et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of

Diet in Renal Disease Study. Ann Intern Med. 1995;123(10):754–762.

Wright JT Jr et al. Effect of blood pressure lowering and antihypertensive drug class on progression of

hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–2431.

Lea J et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease:

results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005;165(8):947–

953.

Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Exp Opin

Pharmacother. 2010;11(16):2675–2686.

Brenner BM et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and

nephropathy. N EnglJ Med. 2001;345(12):861–869.

Lewis EJ et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with

nephropathy due to type 2 diabetes. N EnglJ Med. 2001;345(12):851–860.

Suzuki K et al. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy.

Diabetes Res Clin Pract. 2002;57(3):179–183.

Fried LF et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med.

2013;369(20):1892–1903.

Mann JF et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the

ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–553.

Parving HH et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med.

2012;367(23):2204–2213.

Schroten NF et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic

Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and

Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). Am Heart J.

2015;169(5):693–701.e693.

Bakris GL et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression.

Kidney Int. 2004;65(6):1991–2002.

Smith AC et al. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic

glomerulopathy. Kidney Int. 1998;54(3):889–896.

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and

microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317(7160):713–720.

Chiu DY et al. Sudden cardiac death in haemodialysis patients: preventative options. Nephrology (Carlton).

2014;19(12):740–749.

Rubinger D et al. Sympathetic nervous system function and dysfunction in chronic hemodialysis patients. Semin

Dial. 2013;26(3):333–343.

Weir MA et al. beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc

Nephrol. 2015;26(4):987–996.

Qunibi WY. Dyslipidemia in dialysis patients. Semin Dial. 2015;28(4):345–353.

Palmer SC et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring

dialysis. Cochrane Database Syst Rev. 2014;(5):CD007784.

Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO practice guideline for lipid

management in chronic kidney disease. Kidney Inter Suppl. 2013;3:259–305.

Sarnak MJ et al. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management

in CKD. Am J Kidney Dis. 2015;65(3):354–366.

Baigent C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic

kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet.

2011;377(9784):2181–2192.

Gemfibrozil [package insert]. New York: Parke-Davis; 2010.

Vanholder R et al. Uremic toxins: do we know enough to explain uremia? Blood Purif. 2008;26(1):77–81.

KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic

kidney disease. Am J Kidney Dis. 2007;49(2, Suppl 2):S12–S154.

Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney

disease. Archives of Internal Medicine. 2009;169(12):1156–1162.

Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabetic Medicine.

2008;25(Suppl 2):25–29.

American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35(Suppl

1):S11–S63.

Mallipattu SK, UribarriJ. Advanced glycation end product accumulation: a new enemy to target in chronic kidney

disease? Curr Opin Nephrol Hypertens. 2014;23(6):547–554.

Agius E et al. Familial factors in diabetic nephropathy: an offspring study. Diabet Med. 2006;23(3):331–334.

Breyer MD et al. Insight into the genetics of diabetic nephropathy through the study of mice. Curr Opin Nephrol

Hypertens. 2008;17(1):82–86.

McKnight AJ et al. Genetics of diabetic nephropathy: a long road of discovery. Curr Diab Rep. 2015;15(7):610.

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on

the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J

Med. 1993;329(14):977–986.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin

compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).

Lancet. 1998;352(9131):837–853.

Ismail-Beigi F et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2

diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430.

Group AC et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl

Journal of Medicine. 2008;358(24):2560–2572.

Strippoli GF et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic

nephropathy and delay its progression. J Am Soc Nephrol. 2006;17(4, Suppl 2):S153–S155.

Toto RD. Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr Opin Nephrol

Hypertens. 2010;19(5):444–449.

Schaefer TJ, Wolford RW. Disorders of potassium. Emerg Med Clin N Am. 2005;23(3):723–747, viii–ix.

Gennari FJ, Segal AS. Hyperkalemia: an adaptive response in chronic renal insufficiency. Kidney Int.

100.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

2002;62(1):1–9.

Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol.

2010;6(5):274–285.

Goraya N et al. A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with

fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol. 2013;8(3):371–381.

Yaqoob MM. Treatment of acidosis in CKD. Clin J Am Soc Nephrol. 2013;8(3):342–343.

de Brito-Ashurst I et al. Bicarbonate supplementation slows progression of CKD and improves nutritionalstatus.

J Am Soc Nephrol. 2009;20(9):2075–2084.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice

guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone

disorder (CKD-MBD). Kidney Int Suppl. 2009;76(Suppl 113):S1–S130.

Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline

for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–335.

Kazmi WH et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis.

2001;38(4):803–812.

Cerasola G et al. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a

review. J Nephrol. 2011;24(1):1–10.

Pfeffer MA et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med.

2009;361(21):2019–2032.

Singh AK et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med.

2006;355(20):2085–2098.

Drueke TB et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N EnglJ

Med. 2006;355(20):2071–2084.

Foley RN et al. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a

randomized trial. Clin J Am Soc Nephrol. 2009;4(4):726–733.

Collins AJ. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int Suppl.

2002(80):44–48.

Pascual J et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin

in patients on hemodialysis: a prospective study. Clin Nephrol. 1991;35(6):280–287.

Chertow GM et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant.

2006;21(2):378–382.

Blaustein DA et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with

chronic kidney disease. Kidney Int Suppl. 2003(87):S72–S77.

Agarwal R et al. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int.

2015;88(4):905–914.

INFeD (iron dextran injection, USP) [package insert]. Sorham Park, NJ: Schein Pharmaceutical; 2006.

Larson DS, Coyne DW. Update on intravenous iron choices. Curr Opin Nephrol Hypertens. 2014;23(2):186–

191.

Wang C et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA.

2015;314(19):2062–2068.

Gupta A et al. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen

species generation and subpopulation survival. BMC Nephrol. 2010;11:16.

Schwenk MH. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in

patients with chronic kidney disease. Pharmacotherapy. 2010;30(1):70–79.

Provenzano R et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am

Soc Nephrol. 2009;4(2):386–393.

Feraheme [package insert]. Lexington, MA, AMGA Pharmaceuticals; 2013.

Schiller B et al. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the

United States over a 12-month period. Clin Ther. 2014;36(1):70–83.

Epogen [package insert]. Thousand Oaks, CA: Amgen; 2012.

Suranyi MG et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in

chronic kidney disease. Am J Nephrol. 2003;23(2):106–111.

Aranesp (darbepoetin alfa) [package insert]. Thousand Oaks, CA: Amgen; 2012.

Vlahakos DV et al. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney

Dis. 2010;56(3):558–565.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Casadevall N et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant

erythropoietin. N EnglJ Med. 2002;346(7):469–475.

Schmidt RJ. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off? Exp Opin

Pharmacother. 2009;10(9):1509–1514.

Lai S et al. Early markers of cardiovascular risk in chronic kidney disease. Ren Fail. 2015;37(2):254–261.

Kalpakian MA, Mehrotra R. Vascular calcification and disordered mineral metabolism in dialysis patients. Semin

Dial. 2007;20(2):139–143.

Agarwal R. Hypertension in chronic kidney disease and dialysis: pathophysiology and management. Cardiol Clin.

2005;23(3):237–248.

Park J et al. A comparative effectiveness research study of the change in blood pressure during hemodialysis

treatment and survival. Kidney Int. 2013;84(4):795–802.

Zager PG et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Medical

Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54(2):561–569.

Wilcox CS. New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol.

2002;13(3):798–805.

Paoletti E et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on

prolonged therapy with ACE inhibitors. Am J Kidney Dis. 2002;40(4):728–736.

Yasunari K et al. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive

oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll

Cardiol. 2004;43(11):2116–2123.

Masuo K et al. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens

Res. 2010;33(6):521–528.

Furgeson SB, Chonchol M. Beta-blockade in chronic dialysis patients. Semin Dial. 2008;21(1):43–48.

Gutierrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease:

updating the “trade-off” hypothesis. Clin J Am Soc Nephrol. 2010;5(9):1710–1716.

Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82(7):737–747.

Valle C et al. Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol.

2008;19(12):2430–2436.

Nigwekar SU et al. Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis. 2012;60(1):139–156.

Kalantar-Zadeh K et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic

kidney disease. Clin J Am Soc Nephrol. 2010;5(3):519–530.

Tonelli M et al. Oral phosphate binders in patients with kidney failure. N EnglJ Med. 2010;362(14):1312–1324.

Hill KM et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney

disease. Kidney Int. 2013;83(5):959–966.

Renvela [package insert]. Cambridge, MA: Genzyme Corporation; 2011.

Renagel [package insert]. Cambridge, MA: Genzyme Corporation; 2011.

Block GA et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis

patients. Kidney Int. 2007;71(5):438–441.

Delmez J et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer

carbonate in patients on hemodialysis. Clin Nephrol. 2007;68(6):386–391.

Finn WF, SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the

treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin

Nephrol. 2006;65(3):191–202.

Hutchison AJ et al. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on

the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol. 2009;71(3):286–

295.

D’Haese PC et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate

on renal bone disease in dialysis patients. Kidney Int Suppl. 2003(85):S73–S78.

Altmann P et al. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse

effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int. 2007;71(3):252–

259.

How PP et al. Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers. Clin

Nephrol. 2010;73(5):370–373.

Fosrenol (lanthanum carbonate) [package insert]. Wayne, PA: Shire US; 2014.

Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Am Soc Nephrol. 2015;26(2):493–503.

Velphoro [package insert]. Waltham, MA: Fresenius Medical Care North America; 2013.

Matias PJ et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism,

inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5(5):905–911.

Blair D et al. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol

(vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr. 2008;18(4):375–382.

Saab G et al. Targeting parathyroid hormone levels in dialysis patients. Semin Dial. 2014;27(6):562–565.

Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J

Pharmacol. 2009;158(2):395–412.

Valdivielso JM, Ayus JC. Role of vitamin D receptor activators on cardiovascular risk. Kidney Int Suppl.

2008(111):S44–S49.

Zemplar (paricalcitol) [package insert]. Abbott Park, IL: Abbott Laboratories; 2014.

Joist HE et al. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in

hemodialysis patients. Clin Nephrol. 2006;65(5):335–341.

Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation.